2022 Annual Meeting Virtual Experience | PL2 - Controversies in Neurology Plenary Session

Date Sunday 04/24/22

Time 05:30 PM - 06:30 PM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Plenary Session

Director(s) Martinson K. Arnan, MD, FAAN

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives This session features experts discussing the most current and controversial issues in neuroscience. Tune in for a scholarly debate between two expert speakers, each advocating for one side of a single topic, followed by a rebuttal.

CME Available 1.00 CME credit

Program Materials Program Evaluations

Event Timeline
05:30 PM - 05:35 PM EDT	Introduction	Introduction Martinson K. Arnan, MD, FAAN
05:35 PM - 05:47 PM EDT	Speaker	Yes: Aducanumab: To Prescribe or Not Prescribe Alireza Atri, MD, PhD
05:47 PM - 05:59 PM EDT	Speaker	No: Aducanumab: To Prescribe or Not Prescribe David S. Knopman, MD, FAAN
05:59 PM - 06:04 PM EDT	Speaker	Rebuttal: Aducanumab: To Prescribe or Not Prescribe Alireza Atri, MD, PhD
06:04 PM - 06:09 PM EDT	Speaker	Rebuttal: Aducanumab: To Prescribe or Not Prescribe David S. Knopman, MD, FAAN
06:09 PM - 06:30 PM EDT	Q&A	Fireside Chat Martinson K. Arnan, MD, FAAN, David S. Knopman, MD, FAAN, Alireza Atri, MD, PhD

Faculty Disclosures
Martinson K. Arnan, MD, FAAN	Dr. Arnan has nothing to disclose.
David S. Knopman, MD, FAAN	Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Alireza Atri, MD, PhD	Dr. Atri has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Prothena. Dr. Atri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eisai. Dr. Atri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. Atri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Atri has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Atri has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. Dr. Atri has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. Dr. Atri has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lunbeck. The institution of Dr. Atri has received research support from National Institute of Aging (NIA). The institution of Dr. Atri has received research support from AZ Department of Health Services. The institution of Dr. Atri has received research support from Gates Ventures. The institution of Dr. Atri has received research support from Multiple companies, universities & consortia for contracted clinical trials to institution. The institution of Dr. Atri has received research support from Washington University in St. Louis. The institution of Dr. Atri has received research support from Foundation for NIH. The institution of Dr. Atri has received research support from ACTC/NIH. Dr. Atri has received publishing royalties from a publication relating to health care.